Li MC, Hertz R, Bergenstal DM. Therapy of choriocarcinoma and related trophoblastic tumors with folic acid and purine antagonists. N Engl J Med. 1958;259:66–74.

Article  CAS  PubMed  Google Scholar 

Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315:550–4.

Article  CAS  PubMed  Google Scholar 

Kakizuka A, Miller WH Jr., Umesono K, Warrell RP Jr., Frankel SR, Murty VV, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991;66:663–74.

Article  CAS  PubMed  Google Scholar 

van Dongen JJ, Langerak AW, Bruggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–317.

Article  PubMed  Google Scholar 

Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006;20:1925–30.

Article  CAS  PubMed  Google Scholar 

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34:966–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, et al. Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol. 2017;35:298–305.

Article  PubMed  Google Scholar 

Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gomez Casares MT, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia. 2017;31:1525–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Radich JP, Hochhaus A, Masszi T, Hellmann A, Stentoft J, Casares MTG, et al. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia. 2021;35:1344–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gale RP, Chen J. How should we interpret conclusions of TKI-stopping studies. Leukemia. 2023;37:2343–5.

Article  PubMed  PubMed Central  Google Scholar 

Chen J, Gale RP. Response to Pfirrmann et al.‘s comment on How should we interpret conclusions of TKI-stopping studies. Leukemia. 2024;38:463–4.

Article  PubMed  Google Scholar 

Rousselot P, Charbonnier A, Cony-Makhoul P, Agape P, Nicolini FE, Varet B, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424–30.

Article  CAS  PubMed  Google Scholar 

Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia—a Europe Against Cancer program. Leukemia. 2003;17:2318–57.

Article  CAS  PubMed  Google Scholar 

Roschewski M, Stetler-Stevenson M, Yuan C, Mailankody S, Korde N, Landgren O. Minimal residual disease: what are the minimum requirements? J Clin Oncol. 2014;32:475–6.

Article  PubMed  Google Scholar 

Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, et al. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015;29:999–1003.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e46.

Article  PubMed  Google Scholar 

Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.

Article  PubMed  Google Scholar 

Kasi PM, Fehringer G, Taniguchi H, Starling N, Nakamura Y, Kotani D, et al. Impact of circulating tumor DNA-based detection of molecular residual disease on the conduct and design of clinical trials for solid tumors. JCO Precis Oncol. 2022;6:e2100181.

Article  PubMed  PubMed Central  Google Scholar 

Bradbury C, Houlton AE, Akiki S, Gregg R, Rindl M, Khan J, et al. Prognostic value of monitoring a candidate immunophenotypic leukaemic stem/progenitor cell population in patients allografted for acute myeloid leukaemia. Leukemia. 2015;29:988–91.

Article  CAS  PubMed  Google Scholar 

Klyuchnikov E, Badbaran A, Massoud R, Freiberger P, Wolschke C, Ayuk F, et al. Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR. Leukemia. 2024;38:386–8.

Article  CAS  PubMed  Google Scholar 

Nakamura S, Yokoyama K, Shimizu E, Yusa N, Kondoh K, Ogawa M, et al. Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS. Blood. 2019;133:2682–95.

Article  CAS  PubMed  Google Scholar 

Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, et al. Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv. 2020;4:1670–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Butturini A, Klein J, Gale RP. Modeling minimal residual disease (MRD)-testing. Leuk Res. 2003;27:293–300.

Article  PubMed  Google Scholar 

Radich JP, Gehly G, Gooley T, Bryant E, Clift RA, Collins S, et al. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood. 1995;85:2632–8.

Article  CAS  PubMed  Google Scholar 

Olavarria E, Kanfer E, Szydlo R, Kaeda J, Rezvani K, Cwynarski K, et al. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2001;97:1560–5.

Article  CAS  PubMed  Google Scholar 

Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, et al. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol. 2009;27:377–84.

Article  PubMed  Google Scholar 

Othus M, Wood BL, Stirewalt DL, Estey EH, Petersdorf SH, Appelbaum FR, et al. Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. Leukemia. 2016;30:2080–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Estey E, Gale RP. How good are we at predicting the fate of someone with acute myeloid leukaemia? Leukemia. 2017;31:1255–8.

Article  CAS  PubMed  Google Scholar 

Garcia-Pardo M, Makarem M, Li JJN, Kelly D, Leighl NB. Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges. Br J Cancer. 2022;127:592–602.

Article  PubMed  PubMed Central  Google Scholar 

Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol. 2013;31:3889–97.

Article  PubMed  Google Scholar 

Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood. 2013;122:1813–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK, et al. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol. 2013;31:4123–31.

Article  PubMed  Google Scholar 

Shayegi N, Kramer M, Bornhauser M, Schaich M, Schetelig J, Platzbecker U, et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood. 2013;122:83–92.

Article  CAS  PubMed  Google Scholar 

Ravandi F, Jorgensen JL, Thomas DA, O’Brien S, Garris R, Faderl S, e